ID   BCWM.1/IR
AC   CVCL_VJ30
SY   BCWM_1/IR; BC/IR
DR   cancercelllines; CVCL_VJ30
DR   Cosmic; 2645643
DR   Wikidata; Q93424848
RX   PubMed=25382610;
RX   PubMed=28548645;
CC   Selected for resistance to: ChEBI; CHEBI:76612; Ibrutinib (Imbruvica).
CC   Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C80307; Waldenstrom macroglobulinemia
DI   ORDO; Orphanet_33226; Waldenstrom macroglobulinemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A035 ! BCWM.1
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 05-10-23; Version: 7
//
RX   PubMed=25382610; DOI=10.1038/bcj.2014.74;
RA   Chitta K.S., Paulus A., Caulfield T.R., Akhtar S., Blake M.K.K.,
RA   Ailawadhi S., Knight J., Heckman M.G., Pinkerton A.B., Chanan-Khan A.A.;
RT   "Nimbolide targets BCL2 and induces apoptosis in preclinical models of
RT   Waldenstroms macroglobulinemia.";
RL   Blood Cancer J. 4:e260.1-e260.10(2014).
//
RX   PubMed=28548645; DOI=10.1038/bcj.2017.40;
RA   Paulus A., Akhtar S., Yousaf H.M., Manna A., Paulus S.M., Bashir Y.,
RA   Caulfield T.R., Blake M.K.K., Chitta K.S., Wang X., Asmann Y.,
RA   Hudec R., Springer W., Ailawadhi S., Chanan-Khan A.A.;
RT   "Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or
RT   CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through
RT   upregulation of Bcl-2 and AKT resulting in vulnerability towards
RT   venetoclax or MK2206 treatment.";
RL   Blood Cancer J. 7:e565.1-e565.11(2017).
//